Login / Signup

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Christopher D GockeDouglas E Gladstone
Published in: British journal of haematology (2017)
Keyphrases
  • diffuse large b cell lymphoma
  • low dose
  • high dose
  • free survival
  • chronic lymphocytic leukemia
  • hodgkin lymphoma